Is hyaluronic acid the perfect excipient for the pharmaceutical need?

Hyaluronic acid Modification Mucoadhesion Polymer Structure Thiomers Tissue

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 May 2021
Historique:
received: 09 02 2021
revised: 31 03 2021
accepted: 05 04 2021
pubmed: 13 4 2021
medline: 22 6 2021
entrez: 12 4 2021
Statut: ppublish

Résumé

Hyaluronic acid has become an interesting and important polymer as an excipient for pharmaceutical products due to its beneficial properties, like solubility, biocompatibility and biodegradation. To improve the properties of hyaluronic acid, different possibilities for chemical modifications are presented, and the opportunities as novel systems for drug delivery are discussed. This review gives an overview over the production of hyaluronic acid, the possibilities of its chemical modification and the current state of in vitro and in vivo research. Furthermore, market approved and commercially available products are reviewed and derivatives undergoing clinical trials and applying for market approval are shown. In particular, hyaluronic acid has been studied for different administrations in rheumatology, ophthalmology, local anesthetics, cancer treatment and bioengineering of tissues. The present work concludes with perspectives for future administration of pharmaceuticals based on hyaluronic acid.

Identifiants

pubmed: 33845151
pii: S0378-5173(21)00394-X
doi: 10.1016/j.ijpharm.2021.120589
pii:
doi:

Substances chimiques

Excipients 0
Pharmaceutical Preparations 0
Polymers 0
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

120589

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Daniela Harrer (D)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Eva Sanchez Armengol (E)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Julian D Friedl (JD)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Aamir Jalil (A)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Max Jelkmann (M)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Christina Leichner (C)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria.

Flavia Laffleur (F)

Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria. Electronic address: Flavia.Laffleur@uibk.ac.at.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Humans Hyaluronic Acid Osteoarthritis, Hip Female Middle Aged
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Semiconductors Photosynthesis Polymers Carbon Dioxide Bacteria

Classifications MeSH